董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Keith Crandell | 男 | Director | 64 | 27.25万美元 | 336.16 | 2024-01-01 |
| Emily M. Leproust | 女 | Chief Executive Officer and Board Chair | 51 | 799.86万美元 | 70.83 | 2024-01-01 |
| William Banyai | 男 | Senior Vice President of Advanced Development, General Manager of Data Storage and Director | 69 | 281.64万美元 | 70.83 | 2024-01-01 |
| Xiaoying Mai | 女 | Director | 36 | 27.00万美元 | 未持股 | 2024-01-01 |
| Jan Johannessen | 男 | Director | 68 | 28.50万美元 | 未持股 | 2024-01-01 |
| Melissa A. Starovasnik | 女 | Director | 58 | 27.66万美元 | 未持股 | 2024-01-01 |
| Robert B. Chess | 男 | Lead Independent Director | 67 | 30.40万美元 | 6.98 | 2024-01-01 |
| Nelson C. Chan | 男 | Director | 63 | 28.50万美元 | 未持股 | 2024-01-01 |
| Robert Ragusa | 男 | Director | 65 | 27.13万美元 | 170.21 | 2024-01-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Emily M. Leproust | 女 | Chief Executive Officer and Board Chair | 51 | 799.86万美元 | 70.83 | 2024-01-01 |
| Paula Green | 女 | Senior Vice President of Human Resources | 57 | 248.74万美元 | 未持股 | 2024-01-01 |
| Patrick Finn | 男 | President and Chief Operating Officer | 53 | 522.79万美元 | 未持股 | 2024-01-01 |
| Dennis Cho | 男 | Senior Vice President, General Counsel, Secretary and Chief Ethics and Compliance Officer | 53 | 196.07万美元 | 未持股 | 2024-01-01 |
| Robert Werner | 男 | Chief Accounting Officer | 50 | 未披露 | 未持股 | 2024-01-01 |
| James M. Thorburn | 男 | Chief Financial Officer | 68 | 181.36万美元 | 未持股 | 2024-01-01 |
董事简历
中英对照 | 中文 | 英文- Keith Crandell
-
Keith Crandell自2013年10月起担任Twist Bioscience Corporation董事会成员。Crandell先生是Arch Venture Management，L.P.的董事总经理，该公司的前身是一家自1986年以来专注于早期技术公司的风险投资公司。Crandell先生是多家私营公司的董事，同时也是Quanterix Corporation的董事会成员，Quanterix Corporation是一家上市公司，专注于用于传染病筛查和治疗的数字生物标志物检测，908 Devices Inc.是一家上市公司，专注于需求点化学和生物分子分析设备以及DA32 Life Science Tech Acquisition Corp.。2007年至2019年，他在Adesto Technologies Corporation的董事会任职，Adesto Technologies Corporation是一家上市公司，上市公司是一家上市公司，提供专用和超低功耗的非易失性存储器产品。Crandell先生拥有圣劳伦斯大学化学和数学学士学位、德克萨斯大学阿灵顿分校化学硕士学位和芝加哥大学工商管理硕士学位。
Keith Crandell,has served on Twist Bioscience Corporation Board since October 2013. Mr. Crandell is a Managing Director of ARCH Venture Management, L.P., and its predecessor, a venture capital firm focused on early-stage technology companies, since 1986. Mr. Crandell is a director of several private companies and also serves on the board of directors of 908 Devices Inc., a publicly traded company focused on point-of-need chemical and biomolecular analysis devices. From 2007 to 2019, he served on the board of directors of Adesto Technologies Corporation, a publicly traded provider of application-specific and ultra-low power non-volatile memory products. Mr. Crandell holds a B.S. in Chemistry and Mathematics from St.Lawrence University, an M.S. in Chemistry from the University of Texas, Arlington, and an M.B.A. from the University of Chicago. - Keith Crandell自2013年10月起担任Twist Bioscience Corporation董事会成员。Crandell先生是Arch Venture Management，L.P.的董事总经理，该公司的前身是一家自1986年以来专注于早期技术公司的风险投资公司。Crandell先生是多家私营公司的董事，同时也是Quanterix Corporation的董事会成员，Quanterix Corporation是一家上市公司，专注于用于传染病筛查和治疗的数字生物标志物检测，908 Devices Inc.是一家上市公司，专注于需求点化学和生物分子分析设备以及DA32 Life Science Tech Acquisition Corp.。2007年至2019年，他在Adesto Technologies Corporation的董事会任职，Adesto Technologies Corporation是一家上市公司，上市公司是一家上市公司，提供专用和超低功耗的非易失性存储器产品。Crandell先生拥有圣劳伦斯大学化学和数学学士学位、德克萨斯大学阿灵顿分校化学硕士学位和芝加哥大学工商管理硕士学位。
- Keith Crandell,has served on Twist Bioscience Corporation Board since October 2013. Mr. Crandell is a Managing Director of ARCH Venture Management, L.P., and its predecessor, a venture capital firm focused on early-stage technology companies, since 1986. Mr. Crandell is a director of several private companies and also serves on the board of directors of 908 Devices Inc., a publicly traded company focused on point-of-need chemical and biomolecular analysis devices. From 2007 to 2019, he served on the board of directors of Adesto Technologies Corporation, a publicly traded provider of application-specific and ultra-low power non-volatile memory products. Mr. Crandell holds a B.S. in Chemistry and Mathematics from St.Lawrence University, an M.S. in Chemistry from the University of Texas, Arlington, and an M.B.A. from the University of Chicago.
- Emily M. Leproust
-
EmilyM.Leproust自2013年4月起担任我们的总裁兼首席执行官，并担任董事会成员，自2018年10月起担任董事会主席。共同创立Twist公司之前，LeProust博士曾担任安捷伦公司（Agilent）的多种职务，最近担任其应用和化学研发董事（从2009年2月到2013年4月）。LeProust博士拥有硕士学位。the Lyon School of Industrial Chemistry的工业化学博士学位和the University of Houston的有机化学博士学位。
Emily M. Leproust,has served as Twist Bioscience Corporation Chief Executive Officer and a member of Twist Bioscience Corporation Board since April 2013, Twist Bioscience Corporation President from April 2013 to October 2022 and Chair of Twist Bioscience Corporation Board since October 2018. Prior to co-founding Twist, Dr. Leproust served in various positions at Agilent, most recently as its Director, Applications and Chemistry R&D from February 2009 to April 2013. In addition, Dr. Leproust has served on GeneDx Holdings Corp.'s (formerly known as Sema4 Holdings Corp.) board of directors since September 2020. Dr. Leproust holds a M.Sc. in Industrial Chemistry from the Lyon School of Industrial Chemistry and a Ph.D. in Organic Chemistry from the University of Houston. - EmilyM.Leproust自2013年4月起担任我们的总裁兼首席执行官，并担任董事会成员，自2018年10月起担任董事会主席。共同创立Twist公司之前，LeProust博士曾担任安捷伦公司（Agilent）的多种职务，最近担任其应用和化学研发董事（从2009年2月到2013年4月）。LeProust博士拥有硕士学位。the Lyon School of Industrial Chemistry的工业化学博士学位和the University of Houston的有机化学博士学位。
- Emily M. Leproust,has served as Twist Bioscience Corporation Chief Executive Officer and a member of Twist Bioscience Corporation Board since April 2013, Twist Bioscience Corporation President from April 2013 to October 2022 and Chair of Twist Bioscience Corporation Board since October 2018. Prior to co-founding Twist, Dr. Leproust served in various positions at Agilent, most recently as its Director, Applications and Chemistry R&D from February 2009 to April 2013. In addition, Dr. Leproust has served on GeneDx Holdings Corp.'s (formerly known as Sema4 Holdings Corp.) board of directors since September 2020. Dr. Leproust holds a M.Sc. in Industrial Chemistry from the Lyon School of Industrial Chemistry and a Ph.D. in Organic Chemistry from the University of Houston.
- William Banyai
-
William Banyai自2020年1月起担任我们的高级开发高级副总裁兼数据存储总经理，此前曾于2013年4月至2019年12月担任我们的首席运营官。2013年4月以来，他一直担任我们的董事会成员。在共同创立Twist之前，Banyai博士从2006年4月到2013年3月担任Complete Genomics Inc.（一家生命科学公司，开发和商业化人类基因组测序和分析平台）硬件工程的Vice President。Banyai博士之前也是Glimmerglass Networks的董事，该公司是SDN支持的智能光交换和光网络管理解决方案的供应商。Banyai博士拥有密歇根大学（University of Michigan）物理学学士学位和电气科学硕士学位，南加州大学（University of Southern California）电气工程学位工程师和亚利桑那大学（University of Arizona）光学科学博士学位。
William Banyai,has served as Twist Bioscience Corporation Senior Vice President of Advanced Development and General Manager of Data Storage since January 2020 and previously served as Twist Bioscience Corporation Chief Operating Officer from April 2013 to December 2019. He has been a member of Twist Bioscience Corporation Board since April 2013 and will serve as a director until the Annual Meeting. Prior to co-founding Twist, from April 2006 to March 2013, Dr. Banyai was the Vice President of Hardware Engineering at Complete Genomics Inc., a life sciences company that developed and commercialized a platform for sequencing and analyzing human genomes. Dr. Banyai was also previously a director at Glimmerglass Networks, a supplier of SDN enabled Intelligent Optical Switching and Optical Network Management solutions. Dr. Banyai holds a B.S. in Physics and an M.S. in Electrical Science from the University of Michigan, an Engineer of Electrical Engineering degree from the University of Southern California and a Ph.D. in Optical Science from the University of Arizona. - William Banyai自2020年1月起担任我们的高级开发高级副总裁兼数据存储总经理，此前曾于2013年4月至2019年12月担任我们的首席运营官。2013年4月以来，他一直担任我们的董事会成员。在共同创立Twist之前，Banyai博士从2006年4月到2013年3月担任Complete Genomics Inc.（一家生命科学公司，开发和商业化人类基因组测序和分析平台）硬件工程的Vice President。Banyai博士之前也是Glimmerglass Networks的董事，该公司是SDN支持的智能光交换和光网络管理解决方案的供应商。Banyai博士拥有密歇根大学（University of Michigan）物理学学士学位和电气科学硕士学位，南加州大学（University of Southern California）电气工程学位工程师和亚利桑那大学（University of Arizona）光学科学博士学位。
- William Banyai,has served as Twist Bioscience Corporation Senior Vice President of Advanced Development and General Manager of Data Storage since January 2020 and previously served as Twist Bioscience Corporation Chief Operating Officer from April 2013 to December 2019. He has been a member of Twist Bioscience Corporation Board since April 2013 and will serve as a director until the Annual Meeting. Prior to co-founding Twist, from April 2006 to March 2013, Dr. Banyai was the Vice President of Hardware Engineering at Complete Genomics Inc., a life sciences company that developed and commercialized a platform for sequencing and analyzing human genomes. Dr. Banyai was also previously a director at Glimmerglass Networks, a supplier of SDN enabled Intelligent Optical Switching and Optical Network Management solutions. Dr. Banyai holds a B.S. in Physics and an M.S. in Electrical Science from the University of Michigan, an Engineer of Electrical Engineering degree from the University of Southern California and a Ph.D. in Optical Science from the University of Arizona.
- Xiaoying Mai
-
Xiaoying Mai自2018年7月以来一直担任我们的董事会成员。Mai女士是广发信德投资管理有限公司（GF Xinde Investment Management Co.Ltd）的投资总监，该公司是一家位于中国的风险投资公司，专注于投资生物技术公司，她自2015年6月起担任该职位。麦女士此前曾于2012年12月至2015年6月担任广发证券股份有限公司（一家在香港公开上市的公司）的财务经理，在那里她专门为公开披露和税收管理准备财务信息。麦女士还曾担任IPSAS计划-国际公共部门会计准则的成员，并于2011年与联合国合作。麦女士拥有广东外国语大学工商管理学士学位和乔治华盛顿大学会计学硕士学位。
Xiaoying Mai,has served on Twist Bioscience Corporation Board since July 2018. Ms. Mai is an Executive Director of GF Investments (Hong Kong), a private equity investment firm based in Hong Kong China that specializes in investing in biotechnology companies, a position she has held since Nov 2021. Ms. Mai previously served as an investment director of GF Xinde, a venture arm for Guangfa Securities Co., Ltd, a publicly listed company in Hong Kong from 2015 to 2021, before which she was with the finance department of the group, where she specialized in preparing financial information for public disclosure and tax management. Ms. Mai holds a B.A. in Business Management from the Guangdong University of Foreign Studies and a M.A. in accountancy from George Washington University. - Xiaoying Mai自2018年7月以来一直担任我们的董事会成员。Mai女士是广发信德投资管理有限公司（GF Xinde Investment Management Co.Ltd）的投资总监，该公司是一家位于中国的风险投资公司，专注于投资生物技术公司，她自2015年6月起担任该职位。麦女士此前曾于2012年12月至2015年6月担任广发证券股份有限公司（一家在香港公开上市的公司）的财务经理，在那里她专门为公开披露和税收管理准备财务信息。麦女士还曾担任IPSAS计划-国际公共部门会计准则的成员，并于2011年与联合国合作。麦女士拥有广东外国语大学工商管理学士学位和乔治华盛顿大学会计学硕士学位。
- Xiaoying Mai,has served on Twist Bioscience Corporation Board since July 2018. Ms. Mai is an Executive Director of GF Investments (Hong Kong), a private equity investment firm based in Hong Kong China that specializes in investing in biotechnology companies, a position she has held since Nov 2021. Ms. Mai previously served as an investment director of GF Xinde, a venture arm for Guangfa Securities Co., Ltd, a publicly listed company in Hong Kong from 2015 to 2021, before which she was with the finance department of the group, where she specialized in preparing financial information for public disclosure and tax management. Ms. Mai holds a B.A. in Business Management from the Guangdong University of Foreign Studies and a M.A. in accountancy from George Washington University.
- Jan Johannessen
-
Jan Johannessen自2018年10月以来一直担任我们的董事会成员。Johannessen先生目前担任Iglobe Partners的顾问，这是一家风险投资公司。Johannessen先生于2013年5月至2017年8月担任半导体公司Conexant Systems，LLC的首席运营官兼秘书，并于2013年5月至2016年5月担任其首席财务官，并于2016年5月至2017年8月担任其首席执行官。Johannessen从2008年8月到2013年5月担任REC Silicon ASA（一家在奥斯陆证券交易所上市的公司）首席财务官和秘书。他曾于2008年5月至2008年8月担任上市公司Lattice Semiconductor Corporation的临时首席执行官兼总裁，并于2003年12月至2008年5月担任Lattice Semiconductor Corporation的首席财务官兼秘书。Johannessen先生拥有休斯顿大学（University of Houston）的工商管理学士学位，以及亚利桑那州立大学（Arizona State University）的国际商务工商管理硕士学位。
Jan Johannessen,has served on Twist Bioscience Corporation Board since October 2018. Mr. Johannessen currently serves as an advisor to iGlobe Partners, a venture capital company. Mr. Johannessen served as Chief Operating Officer and Secretary at Conexant Systems, LLC, a semiconductor company, from May 2013 to August 2017 and also served as its Chief Financial Officer from May 2013 to May 2016 and as its Chief Executive Officer from May 2016 to August 2017. Mr. Johannessen served as Chief Financial Officer and Secretary at REC Silicon ASA, a company listed on the Oslo stock exchange from August 2008 to May 2013. He served as Interim Chief Executive Officer and President at Lattice Semiconductor Corporation, a publicly traded company, from May 2008 to August 2008 and as Chief Financial Officer and Secretary at Lattice Semiconductor Corporation from December 2003 to May 2008. Mr. Johannessen holds a B.S. in Business from the University of Houston, and an M.B.A. in International Business from Arizona State University. - Jan Johannessen自2018年10月以来一直担任我们的董事会成员。Johannessen先生目前担任Iglobe Partners的顾问，这是一家风险投资公司。Johannessen先生于2013年5月至2017年8月担任半导体公司Conexant Systems，LLC的首席运营官兼秘书，并于2013年5月至2016年5月担任其首席财务官，并于2016年5月至2017年8月担任其首席执行官。Johannessen从2008年8月到2013年5月担任REC Silicon ASA（一家在奥斯陆证券交易所上市的公司）首席财务官和秘书。他曾于2008年5月至2008年8月担任上市公司Lattice Semiconductor Corporation的临时首席执行官兼总裁，并于2003年12月至2008年5月担任Lattice Semiconductor Corporation的首席财务官兼秘书。Johannessen先生拥有休斯顿大学（University of Houston）的工商管理学士学位，以及亚利桑那州立大学（Arizona State University）的国际商务工商管理硕士学位。
- Jan Johannessen,has served on Twist Bioscience Corporation Board since October 2018. Mr. Johannessen currently serves as an advisor to iGlobe Partners, a venture capital company. Mr. Johannessen served as Chief Operating Officer and Secretary at Conexant Systems, LLC, a semiconductor company, from May 2013 to August 2017 and also served as its Chief Financial Officer from May 2013 to May 2016 and as its Chief Executive Officer from May 2016 to August 2017. Mr. Johannessen served as Chief Financial Officer and Secretary at REC Silicon ASA, a company listed on the Oslo stock exchange from August 2008 to May 2013. He served as Interim Chief Executive Officer and President at Lattice Semiconductor Corporation, a publicly traded company, from May 2008 to August 2008 and as Chief Financial Officer and Secretary at Lattice Semiconductor Corporation from December 2003 to May 2008. Mr. Johannessen holds a B.S. in Business from the University of Houston, and an M.B.A. in International Business from Arizona State University.
- Melissa A. Starovasnik
-
Melissa A.Starovasnik自2021年8月起担任我们的董事会成员。在加入我们的董事会之前，Starovasnik博士于2017年至2021年担任Genentech, Inc.“；Genentech”；的研究高级科学顾问，并在蛋白质和抗体药物的发现和开发方面拥有近30年的经验。从1993年到2017年，Starovasnik博士在基因泰克担任越来越重要的职务，并且是研究领导团队的重要成员。作为副总裁，蛋白质科学和大分子药物发现主管（从2011年到2017年），她负责蛋白质和抗体疗法的发现，并监督一个由近200名员工组成的组织。Starovasnik博士拥有华盛顿大学化学学士学位和生物化学博士学位。她目前还担任Aarvik Therapeutics Inc、Ambrx Inc和Denali Therapeutics Inc.的科学顾问委员会成员。
Melissa A. Starovasnik,has served on Twist Bioscience Corporation Board since August 2021. Prior to joining Twist Bioscience Corporation Board, Dr. Starovasnik served as Senior Scientific Advisor, Research at Genentech, Inc. ("Genentech") from 2017 to 2021. From 1993 to 2017, Dr. Starovasnik served at Genentech in roles of increasing responsibility and was an integral member of the research leadership team. As Vice President, Protein Sciences and Head of Large Molecule Drug Discovery from 2011 to 2017, she was responsible for protein and antibody therapeutics discovery, overseeing an organization of nearly 200 employees. Dr. Starovasnik holds a B.S. in Chemistry and a Ph.D. in Biochemistry from the University of Washington. She also currently serves as a Scientific Advisory Board Member for Aarvik Therapeutics Inc, Ambrx Inc, Denali Therapeutics Inc., and Expansion Therapeutics, among other advisory roles. - Melissa A.Starovasnik自2021年8月起担任我们的董事会成员。在加入我们的董事会之前，Starovasnik博士于2017年至2021年担任Genentech, Inc.“；Genentech”；的研究高级科学顾问，并在蛋白质和抗体药物的发现和开发方面拥有近30年的经验。从1993年到2017年，Starovasnik博士在基因泰克担任越来越重要的职务，并且是研究领导团队的重要成员。作为副总裁，蛋白质科学和大分子药物发现主管（从2011年到2017年），她负责蛋白质和抗体疗法的发现，并监督一个由近200名员工组成的组织。Starovasnik博士拥有华盛顿大学化学学士学位和生物化学博士学位。她目前还担任Aarvik Therapeutics Inc、Ambrx Inc和Denali Therapeutics Inc.的科学顾问委员会成员。
- Melissa A. Starovasnik,has served on Twist Bioscience Corporation Board since August 2021. Prior to joining Twist Bioscience Corporation Board, Dr. Starovasnik served as Senior Scientific Advisor, Research at Genentech, Inc. ("Genentech") from 2017 to 2021. From 1993 to 2017, Dr. Starovasnik served at Genentech in roles of increasing responsibility and was an integral member of the research leadership team. As Vice President, Protein Sciences and Head of Large Molecule Drug Discovery from 2011 to 2017, she was responsible for protein and antibody therapeutics discovery, overseeing an organization of nearly 200 employees. Dr. Starovasnik holds a B.S. in Chemistry and a Ph.D. in Biochemistry from the University of Washington. She also currently serves as a Scientific Advisory Board Member for Aarvik Therapeutics Inc, Ambrx Inc, Denali Therapeutics Inc., and Expansion Therapeutics, among other advisory roles.
- Robert B. Chess
-
Robert B. Chess，自2014年7月起担任Twist Bioscience Corporation董事会成员，并于2018年10月30日被任命为首席独立董事；Nektar Therapeutics的董事长，自1992年5月起担任董事。2006年3月至2007年1月，他担任本公司的代理总裁、首席执行官；1999年4月至2007年1月，担任执行董事长。1998年8月至2000年4月，他还担任本公司的联席首席执行官；1991年12月至1998年8月，担任总裁；1992年5月至1998年8月，担任首席执行官。之前，他曾是Penederm的联合创始人、总裁，这是一个上市的皮肤科制药公司，后来出售给Mylan Laboratories。他曾在Intel Corporation 和 Metaphor Computer Systems（现为IBM的分部）担任过管理职务；作为白宫实习生，他是布什总统白宫工作人员的第一批成员，曾担任White House Office of Economic and Domestic Policy的副主任。1997年直到2009年退休，他都是Biotechnology Industry Organization （BIO）的董事；也曾担任BIO新兴公司部门的主席，及其知识产权委员会联合主席。他是 Bio Ventures for Global Health的首任主席，目前依旧担任董事。他还是 California Institute of Technology的董事、技术转移委员会主席、经济发展委员会受托人。目前，他是OPX Biotechnologies的董事长，这是可再生燃料和化学品领域的私营公司；也是医疗器械私营公司Pelvalon的董事。他现任Stanford Graduate School of Business的教员，在MBA的课程中讲授关于启动技术公司和医疗行业的知识。他以优异成绩获得了California Institute of Technology的工程学士学位，并在Harvard University获得工商管理硕士学位。
Robert B. Chess,has served on Twist Bioscience Corporation Board since July 2014, and he was appointed as lead independent director effective as of October 30, 2018. Mr. Chess is Chairman of the Board of Directors of Nektar Therapeutics, a publicly traded therapeutics company. He has served on the Board of Nektar Therapeutics as either Chief Executive Officer and/or Chairman since 1992 and has held the Chairman position since 1999. Mr. Chess has also served on the Board of Directors of Pharsight Corp., a publicly traded company that provides software and scientific consulting services to pharmaceutical and biotechnology companies, and CoTherix, Inc., a publicly traded biopharmaceutical company. Mr. Chess is also currently a director of two private companies. Mr. Chess currently serves as a lecturer at the Stanford Graduate School of Business, a position he has held since 2004. Mr. Chess holds a B.S. in Engineering with Honors from the California Institute of Technology and an M.B.A. from Harvard University. - Robert B. Chess，自2014年7月起担任Twist Bioscience Corporation董事会成员，并于2018年10月30日被任命为首席独立董事；Nektar Therapeutics的董事长，自1992年5月起担任董事。2006年3月至2007年1月，他担任本公司的代理总裁、首席执行官；1999年4月至2007年1月，担任执行董事长。1998年8月至2000年4月，他还担任本公司的联席首席执行官；1991年12月至1998年8月，担任总裁；1992年5月至1998年8月，担任首席执行官。之前，他曾是Penederm的联合创始人、总裁，这是一个上市的皮肤科制药公司，后来出售给Mylan Laboratories。他曾在Intel Corporation 和 Metaphor Computer Systems（现为IBM的分部）担任过管理职务；作为白宫实习生，他是布什总统白宫工作人员的第一批成员，曾担任White House Office of Economic and Domestic Policy的副主任。1997年直到2009年退休，他都是Biotechnology Industry Organization （BIO）的董事；也曾担任BIO新兴公司部门的主席，及其知识产权委员会联合主席。他是 Bio Ventures for Global Health的首任主席，目前依旧担任董事。他还是 California Institute of Technology的董事、技术转移委员会主席、经济发展委员会受托人。目前，他是OPX Biotechnologies的董事长，这是可再生燃料和化学品领域的私营公司；也是医疗器械私营公司Pelvalon的董事。他现任Stanford Graduate School of Business的教员，在MBA的课程中讲授关于启动技术公司和医疗行业的知识。他以优异成绩获得了California Institute of Technology的工程学士学位，并在Harvard University获得工商管理硕士学位。
- Robert B. Chess,has served on Twist Bioscience Corporation Board since July 2014, and he was appointed as lead independent director effective as of October 30, 2018. Mr. Chess is Chairman of the Board of Directors of Nektar Therapeutics, a publicly traded therapeutics company. He has served on the Board of Nektar Therapeutics as either Chief Executive Officer and/or Chairman since 1992 and has held the Chairman position since 1999. Mr. Chess has also served on the Board of Directors of Pharsight Corp., a publicly traded company that provides software and scientific consulting services to pharmaceutical and biotechnology companies, and CoTherix, Inc., a publicly traded biopharmaceutical company. Mr. Chess is also currently a director of two private companies. Mr. Chess currently serves as a lecturer at the Stanford Graduate School of Business, a position he has held since 2004. Mr. Chess holds a B.S. in Engineering with Honors from the California Institute of Technology and an M.B.A. from Harvard University.
- Nelson C. Chan
-
Nelson C. Chan，2010年3月以来，他担任董事，审计委员会的董事长和薪酬委员会成员。从2006年到2008年，他担任麦哲伦导航公司的首席执行官。从1992年到2006年，陈先生在SanDisk公司里担任过多个高级管理职位，包括最近的消费者业务的执行副总裁和总经理。陈先生是Outerwall董事会的主席，和新思国际注册公司主管。
Nelson C. Chan,has served on Twist Bioscience Corporation Board since May 2019. From 2006 until 2008, Mr. Chan served as Chief Executive Officer of Magellan Navigation, Inc., a leader in the consumer, survey, GIS and OEM GPS navigation and positioning markets. From 1992 through 2006, Mr. Chan held various senior management positions at SanDisk Corporation, a leader in flash memory cards, including most recently as Executive Vice President and General Manager, Consumer Business. From 1983 to 1992, he held marketing and engineering positions at Chip and Technologies, Signetics, and Delco Electronics. Mr. Chan is Chairman of the Board of Synaptics Incorporated, a developer of custom-designed human interface solutions and a member of its Audit Committee and Nominating and Corporate Governance Committee. Mr. Chan is also a director and a member of the Audit Committee and Nominating and Corporate Governance Committee of Deckers Outdoor Corporation. He served as Chairman of the board of Adesto Technologies Corporation from 2010 until it was acquired in 2020 by Dialog Semiconductor PLC, and as a member of the board of Affymetrix Inc. from March 2010 to March 2016 until it was acquired by Thermo Fisher Scientific Inc. Mr. Chan was Chairman of the board of Outerwall Inc. from June 2013 to September 2016 and served on the board from June 2011 to June 2013 until it was acquired by Apollo Global Management. He was a director of Socket Mobile from 2016 until 2019, and as a director of Silicon Laboratories, Inc. from 2007 until 2010. Mr. Chan also currently serves as a member of the board of several privately-held companies. Mr. Chan holds a B.S. degree in electrical and computer engineering from the University of California at Santa Barbara and a M.B.A. from Santa Clara University. - Nelson C. Chan，2010年3月以来，他担任董事，审计委员会的董事长和薪酬委员会成员。从2006年到2008年，他担任麦哲伦导航公司的首席执行官。从1992年到2006年，陈先生在SanDisk公司里担任过多个高级管理职位，包括最近的消费者业务的执行副总裁和总经理。陈先生是Outerwall董事会的主席，和新思国际注册公司主管。
- Nelson C. Chan,has served on Twist Bioscience Corporation Board since May 2019. From 2006 until 2008, Mr. Chan served as Chief Executive Officer of Magellan Navigation, Inc., a leader in the consumer, survey, GIS and OEM GPS navigation and positioning markets. From 1992 through 2006, Mr. Chan held various senior management positions at SanDisk Corporation, a leader in flash memory cards, including most recently as Executive Vice President and General Manager, Consumer Business. From 1983 to 1992, he held marketing and engineering positions at Chip and Technologies, Signetics, and Delco Electronics. Mr. Chan is Chairman of the Board of Synaptics Incorporated, a developer of custom-designed human interface solutions and a member of its Audit Committee and Nominating and Corporate Governance Committee. Mr. Chan is also a director and a member of the Audit Committee and Nominating and Corporate Governance Committee of Deckers Outdoor Corporation. He served as Chairman of the board of Adesto Technologies Corporation from 2010 until it was acquired in 2020 by Dialog Semiconductor PLC, and as a member of the board of Affymetrix Inc. from March 2010 to March 2016 until it was acquired by Thermo Fisher Scientific Inc. Mr. Chan was Chairman of the board of Outerwall Inc. from June 2013 to September 2016 and served on the board from June 2011 to June 2013 until it was acquired by Apollo Global Management. He was a director of Socket Mobile from 2016 until 2019, and as a director of Silicon Laboratories, Inc. from 2007 until 2010. Mr. Chan also currently serves as a member of the board of several privately-held companies. Mr. Chan holds a B.S. degree in electrical and computer engineering from the University of California at Santa Barbara and a M.B.A. from Santa Clara University.
- Robert Ragusa
-
Robert Ragusa，自2013年4月起担任本公司工程和全球运营执行副总裁。在此之前，他从2010年3月起担任本公司全球运营高级副总裁，直到2013年4月他晋升为工程和全球运营执行副总裁。从2007年2月至2010年3月，他担任Bloom Energy的全球运营高级副总裁，这是一家制造燃料电池的私营公司。此前，从2005年6月至2007年2月，他在生产DNA微阵列的上市公司Affymetrix担任全球运营高级副总裁。他获得了康涅狄格大学电气工程学士学位、卡内基 - 梅隆大学的生物医学工程与电气工程硕士学位、康涅狄格大学的财务与营销方向的工商管理硕士学位。
Robert Ragusa,has served on Twist Bioscience Corporation Board since November 2016. Mr. Ragusa is currently the Chief Executive Officer of GRAIL, LLC. ("GRAIL"), a healthcare company focused on early detection of multiple cancers, which was acquired by Illumina, Inc. in August 2021. He has been the Chief Executive Officer of GRAIL since October 2021. Mr. Ragusa served as the Chief Operating Officer of Illumina, Inc., a publicly traded corporation providing sequencing and array-based solutions for genetic and genomic analysis from December 2013 to October 2021. Prior to joining Illumina, Inc., from April 2010 to November 2013, Mr. Ragusa was Executive Vice President, Global Operations and Service at Accuray Incorporated, a radiation oncology company that develops, manufactures, sells and supports cancer treatment solutions. Mr. Ragusa holds a B.S. in Biomedical and Electrical Engineering and an M.B.A. from the University of Connecticut, and an M.S. in Biomedical and Electrical Engineering from Carnegie-Mellon University. - Robert Ragusa，自2013年4月起担任本公司工程和全球运营执行副总裁。在此之前，他从2010年3月起担任本公司全球运营高级副总裁，直到2013年4月他晋升为工程和全球运营执行副总裁。从2007年2月至2010年3月，他担任Bloom Energy的全球运营高级副总裁，这是一家制造燃料电池的私营公司。此前，从2005年6月至2007年2月，他在生产DNA微阵列的上市公司Affymetrix担任全球运营高级副总裁。他获得了康涅狄格大学电气工程学士学位、卡内基 - 梅隆大学的生物医学工程与电气工程硕士学位、康涅狄格大学的财务与营销方向的工商管理硕士学位。
- Robert Ragusa,has served on Twist Bioscience Corporation Board since November 2016. Mr. Ragusa is currently the Chief Executive Officer of GRAIL, LLC. ("GRAIL"), a healthcare company focused on early detection of multiple cancers, which was acquired by Illumina, Inc. in August 2021. He has been the Chief Executive Officer of GRAIL since October 2021. Mr. Ragusa served as the Chief Operating Officer of Illumina, Inc., a publicly traded corporation providing sequencing and array-based solutions for genetic and genomic analysis from December 2013 to October 2021. Prior to joining Illumina, Inc., from April 2010 to November 2013, Mr. Ragusa was Executive Vice President, Global Operations and Service at Accuray Incorporated, a radiation oncology company that develops, manufactures, sells and supports cancer treatment solutions. Mr. Ragusa holds a B.S. in Biomedical and Electrical Engineering and an M.B.A. from the University of Connecticut, and an M.S. in Biomedical and Electrical Engineering from Carnegie-Mellon University.
高管简历
中英对照 | 中文 | 英文- Emily M. Leproust
EmilyM.Leproust自2013年4月起担任我们的总裁兼首席执行官，并担任董事会成员，自2018年10月起担任董事会主席。共同创立Twist公司之前，LeProust博士曾担任安捷伦公司（Agilent）的多种职务，最近担任其应用和化学研发董事（从2009年2月到2013年4月）。LeProust博士拥有硕士学位。the Lyon School of Industrial Chemistry的工业化学博士学位和the University of Houston的有机化学博士学位。
Emily M. Leproust,has served as Twist Bioscience Corporation Chief Executive Officer and a member of Twist Bioscience Corporation Board since April 2013, Twist Bioscience Corporation President from April 2013 to October 2022 and Chair of Twist Bioscience Corporation Board since October 2018. Prior to co-founding Twist, Dr. Leproust served in various positions at Agilent, most recently as its Director, Applications and Chemistry R&D from February 2009 to April 2013. In addition, Dr. Leproust has served on GeneDx Holdings Corp.'s (formerly known as Sema4 Holdings Corp.) board of directors since September 2020. Dr. Leproust holds a M.Sc. in Industrial Chemistry from the Lyon School of Industrial Chemistry and a Ph.D. in Organic Chemistry from the University of Houston.- EmilyM.Leproust自2013年4月起担任我们的总裁兼首席执行官，并担任董事会成员，自2018年10月起担任董事会主席。共同创立Twist公司之前，LeProust博士曾担任安捷伦公司（Agilent）的多种职务，最近担任其应用和化学研发董事（从2009年2月到2013年4月）。LeProust博士拥有硕士学位。the Lyon School of Industrial Chemistry的工业化学博士学位和the University of Houston的有机化学博士学位。
- Emily M. Leproust,has served as Twist Bioscience Corporation Chief Executive Officer and a member of Twist Bioscience Corporation Board since April 2013, Twist Bioscience Corporation President from April 2013 to October 2022 and Chair of Twist Bioscience Corporation Board since October 2018. Prior to co-founding Twist, Dr. Leproust served in various positions at Agilent, most recently as its Director, Applications and Chemistry R&D from February 2009 to April 2013. In addition, Dr. Leproust has served on GeneDx Holdings Corp.'s (formerly known as Sema4 Holdings Corp.) board of directors since September 2020. Dr. Leproust holds a M.Sc. in Industrial Chemistry from the Lyon School of Industrial Chemistry and a Ph.D. in Organic Chemistry from the University of Houston.
- Paula Green
Paula Green自2020年12月起担任我们的人力资源高级副总裁，此前曾于2016年3月至2020年11月担任我们的人力资源Vice President。在加入我们之前，Green女士于2001年3月至2015年9月担任QIAGEN，N.V.（一家为分子诊断，应用测试，学术和制药研究提供样品和分析技术的提供商）人力资源Vice President。Green女士拥有旧金山大学（University of San Francisco）的B.S.组织行为学学位。
Paula Green,has served as Twist Bioscience Corporation Senior Vice President of Human Resources since December 2020 and previously served as Twist Bioscience Corporation Vice President of Human Resources from March 2016 to November 2020. Prior to joining Twist Bioscience Corporation , Ms. Green was Vice President of Human Resources at Qiagen, N.V., a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research from March 2001 to September 2015. Ms. Green holds a B.S. in Organizational Behavior from the University of San Francisco.- Paula Green自2020年12月起担任我们的人力资源高级副总裁，此前曾于2016年3月至2020年11月担任我们的人力资源Vice President。在加入我们之前，Green女士于2001年3月至2015年9月担任QIAGEN，N.V.（一家为分子诊断，应用测试，学术和制药研究提供样品和分析技术的提供商）人力资源Vice President。Green女士拥有旧金山大学（University of San Francisco）的B.S.组织行为学学位。
- Paula Green,has served as Twist Bioscience Corporation Senior Vice President of Human Resources since December 2020 and previously served as Twist Bioscience Corporation Vice President of Human Resources from March 2016 to November 2020. Prior to joining Twist Bioscience Corporation , Ms. Green was Vice President of Human Resources at Qiagen, N.V., a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research from March 2001 to September 2015. Ms. Green holds a B.S. in Organizational Behavior from the University of San Francisco.
- Patrick Finn
Patrick Finn自2019年10月起担任我们的首席商务官，2015年2月至2019年10月担任我们的销售与市场营销Vice President，2018年12月至2019年10月担任我们的商业运营高级副总裁。在加入我们之前，Finn博士是酶学公司（Enzymatics Inc.）的销售Vice President，该公司是一家分子生物学应用酶的开发商，制造商和营销商，2012年1月至2015年3月主要销售给研究和诊断市场的制造商。Finn博士拥有工商管理硕士学位。Heriot-Watt University化学博士学位和the University of Southampton化学博士学位。
Patrick Finn,has served as Twist Bioscience Corporation President and Chief Operating Officer since October 2022. He joined Twist Bioscience Corporation Company in February 2015 as Vice President of Sales and Marketing, was promoted to Senior Vice President of Commercial Operations in December 2018, and served as Twist Bioscience Corporation Chief Commercial Officer from October 2019 to October 2022. Dr. Finn also serves on the Board of Directors of a private corporation. Prior to joining Twist Bioscience Corporation , Dr. Finn was Vice President of Sales at Enzymatics Inc., a developer, manufacturer, and marketer of enzymes for molecular biology applications, sold predominantly to manufacturers in research and diagnostic markets from January 2012 to March 2015. Dr. Finn holds a B.Sc. in Chemistry from Heriot-Watt University and a Ph.D. in Chemistry from the University of Southampton.- Patrick Finn自2019年10月起担任我们的首席商务官，2015年2月至2019年10月担任我们的销售与市场营销Vice President，2018年12月至2019年10月担任我们的商业运营高级副总裁。在加入我们之前，Finn博士是酶学公司（Enzymatics Inc.）的销售Vice President，该公司是一家分子生物学应用酶的开发商，制造商和营销商，2012年1月至2015年3月主要销售给研究和诊断市场的制造商。Finn博士拥有工商管理硕士学位。Heriot-Watt University化学博士学位和the University of Southampton化学博士学位。
- Patrick Finn,has served as Twist Bioscience Corporation President and Chief Operating Officer since October 2022. He joined Twist Bioscience Corporation Company in February 2015 as Vice President of Sales and Marketing, was promoted to Senior Vice President of Commercial Operations in December 2018, and served as Twist Bioscience Corporation Chief Commercial Officer from October 2019 to October 2022. Dr. Finn also serves on the Board of Directors of a private corporation. Prior to joining Twist Bioscience Corporation , Dr. Finn was Vice President of Sales at Enzymatics Inc., a developer, manufacturer, and marketer of enzymes for molecular biology applications, sold predominantly to manufacturers in research and diagnostic markets from January 2012 to March 2015. Dr. Finn holds a B.Sc. in Chemistry from Heriot-Watt University and a Ph.D. in Chemistry from the University of Southampton.
- Dennis Cho
Dennis Cho自2021年9月起担任我们的总法律顾问兼首席道德与合规官。从2021年1月至2021年9月，Cho先生担任治疗性抗体平台公司CytomX医疗公司的副总裁兼助理总法律顾问。在此之前，Cho先生于2019年12月至2021年1月担任生物技术公司Seagen Inc.的执行董事。从2010年10月至2019年12月，Cho先生担任全球综合制药公司新基医药公司的高级公司法律顾问兼执行董事。Cho先生拥有分子细胞生物学遗传学和种族研究的学士学位，以及加州大学伯克利分校的法学博士学位。
Dennis Cho,has served as Twist Bioscience Corporation Senior Vice President, General Counsel, Secretary and Chief Ethics and Compliance Officer since September 2021. From January 2021 to September 2021, Mr. Cho served as Vice President and Assistant General Counsel at CytomX Therapeutics, Inc., a therapeutic antibody platform company. Prior to this, from December 2019 to January 2021, Mr. Cho served as Executive Director for Seagen Inc., a biotechnology company. From October 2010 to December 2019, Mr. Cho was Senior Corporate Counsel and Executive Director for Celgene Corporation, an integrated global pharmaceutical company. Mr. Cho holds a B.S. in Molecular Cell Biology (Genetics), and Ethnic Studies, and a J.D. from University of California, Berkeley.- Dennis Cho自2021年9月起担任我们的总法律顾问兼首席道德与合规官。从2021年1月至2021年9月，Cho先生担任治疗性抗体平台公司CytomX医疗公司的副总裁兼助理总法律顾问。在此之前，Cho先生于2019年12月至2021年1月担任生物技术公司Seagen Inc.的执行董事。从2010年10月至2019年12月，Cho先生担任全球综合制药公司新基医药公司的高级公司法律顾问兼执行董事。Cho先生拥有分子细胞生物学遗传学和种族研究的学士学位，以及加州大学伯克利分校的法学博士学位。
- Dennis Cho,has served as Twist Bioscience Corporation Senior Vice President, General Counsel, Secretary and Chief Ethics and Compliance Officer since September 2021. From January 2021 to September 2021, Mr. Cho served as Vice President and Assistant General Counsel at CytomX Therapeutics, Inc., a therapeutic antibody platform company. Prior to this, from December 2019 to January 2021, Mr. Cho served as Executive Director for Seagen Inc., a biotechnology company. From October 2010 to December 2019, Mr. Cho was Senior Corporate Counsel and Executive Director for Celgene Corporation, an integrated global pharmaceutical company. Mr. Cho holds a B.S. in Molecular Cell Biology (Genetics), and Ethnic Studies, and a J.D. from University of California, Berkeley.
- Robert Werner
Robert Werner，自2023年5月起担任Twist Bioscience Corporation副总裁、首席会计官。在加入Twist Bioscience Corporation之前，Werner先生是Invitae，Inc.的首席会计官。在加入Invitae之前，Werner先生曾担任Proteus Digital Health的财务副总裁和公司财务总监。他此前曾在CardioDX担任公司财务总监和首席会计官，在Bloom Energy担任公司财务总监。他在Spansion，Inc.（超微半导体的衍生公司）担任了一系列越来越重要的职务。Werner先生是注册会计师，拥有杨百翰大学万豪酒店管理学院专业会计硕士学位和会计学学士学位。
Robert Werner,has served as Twist Bioscience Corporation Vice President, Chief Accounting Officer since May 2023. Prior to joining Twist Bioscience Corporation , Mr. Werner was Chief Accounting Officer at Invitae, Inc. Prior to Invitae, Mr. Werner served as Vice President of Finance and Corporate Controller at Proteus Digital Health. He previously served as Corporate Controller and Principal Accounting Officer at CardioDx and as Corporate Controller at Bloom Energy. He held a series of roles of increasing responsibility at Spansion, Inc. (a spinoff of Advanced Micro Devices). Mr. Werner is a Certified Public Accountant and holds a Master's of accountancy in professional accounting and a B.S. degree in Accounting from Brigham Young University's Marriott School of Management.- Robert Werner，自2023年5月起担任Twist Bioscience Corporation副总裁、首席会计官。在加入Twist Bioscience Corporation之前，Werner先生是Invitae，Inc.的首席会计官。在加入Invitae之前，Werner先生曾担任Proteus Digital Health的财务副总裁和公司财务总监。他此前曾在CardioDX担任公司财务总监和首席会计官，在Bloom Energy担任公司财务总监。他在Spansion，Inc.（超微半导体的衍生公司）担任了一系列越来越重要的职务。Werner先生是注册会计师，拥有杨百翰大学万豪酒店管理学院专业会计硕士学位和会计学学士学位。
- Robert Werner,has served as Twist Bioscience Corporation Vice President, Chief Accounting Officer since May 2023. Prior to joining Twist Bioscience Corporation , Mr. Werner was Chief Accounting Officer at Invitae, Inc. Prior to Invitae, Mr. Werner served as Vice President of Finance and Corporate Controller at Proteus Digital Health. He previously served as Corporate Controller and Principal Accounting Officer at CardioDx and as Corporate Controller at Bloom Energy. He held a series of roles of increasing responsibility at Spansion, Inc. (a spinoff of Advanced Micro Devices). Mr. Werner is a Certified Public Accountant and holds a Master's of accountancy in professional accounting and a B.S. degree in Accounting from Brigham Young University's Marriott School of Management.
- James M. Thorburn
自2007年3月以来，James M. Thorburn曾担任董事。自2010年4月以来，他一直从事咨询工作，主要是在私募和初设公司。自2006年8月至2009年2月，他是隶属于Francisco Partners的运营商，这是一家私人股权投资公司，从2009年2月至2010年4月担任Fisker Automotive首席财务官，这是一家插电式混合动力电动汽车制造商。2002年1月至2006年8月，他担任Zilog首席执行官和主席。任Zilog首席执行官前，他担任多个管理职务，包括任 ON Semiconductor高级副总裁兼首席运营官，任Texas Pacific 集团运营顾问，任Zilog首席财务官和任National Semiconductor管理职务。
James M. Thorburn,has served as Twist Bioscience Corporation Chief Financial Officer since April 2018. Prior to joining Twist Bioscience Corporation , Mr. Thorburn served as a member of the Board of Directors of IXYS Corporation, a publicly traded semiconductor company from March 2007 to January 2018. Mr. Thorburn was also Chief Sales Officer and Co-Head of International at Televerde, a demand generation and sales acceleration enterprise, from August 2014 to February 2018. Prior to Televerde, he served as interim CFO of several public and private companies including Enercore, Next Autoworks, Fisker Automotive and Numonyx. Mr. Thorburn served as Chief Executive Officer of Zilog from March 2001 until August 2006. Prior to serving as Chief Executive Officer of Zilog, Mr. Thorburn held various executive positions including Chief Operating Officer of ON Semiconductor, operating consultant with Texas Pacific Group, Chief Financial Officer at Zilog and various management positions at National Semiconductor Corporation. Mr. Thorburn holds a B.Sc. (Hons.) degree from University of Glasgow and passed the Chartered Institute of Management Accountant exams in the United Kingdom.- 自2007年3月以来，James M. Thorburn曾担任董事。自2010年4月以来，他一直从事咨询工作，主要是在私募和初设公司。自2006年8月至2009年2月，他是隶属于Francisco Partners的运营商，这是一家私人股权投资公司，从2009年2月至2010年4月担任Fisker Automotive首席财务官，这是一家插电式混合动力电动汽车制造商。2002年1月至2006年8月，他担任Zilog首席执行官和主席。任Zilog首席执行官前，他担任多个管理职务，包括任 ON Semiconductor高级副总裁兼首席运营官，任Texas Pacific 集团运营顾问，任Zilog首席财务官和任National Semiconductor管理职务。
- James M. Thorburn,has served as Twist Bioscience Corporation Chief Financial Officer since April 2018. Prior to joining Twist Bioscience Corporation , Mr. Thorburn served as a member of the Board of Directors of IXYS Corporation, a publicly traded semiconductor company from March 2007 to January 2018. Mr. Thorburn was also Chief Sales Officer and Co-Head of International at Televerde, a demand generation and sales acceleration enterprise, from August 2014 to February 2018. Prior to Televerde, he served as interim CFO of several public and private companies including Enercore, Next Autoworks, Fisker Automotive and Numonyx. Mr. Thorburn served as Chief Executive Officer of Zilog from March 2001 until August 2006. Prior to serving as Chief Executive Officer of Zilog, Mr. Thorburn held various executive positions including Chief Operating Officer of ON Semiconductor, operating consultant with Texas Pacific Group, Chief Financial Officer at Zilog and various management positions at National Semiconductor Corporation. Mr. Thorburn holds a B.Sc. (Hons.) degree from University of Glasgow and passed the Chartered Institute of Management Accountant exams in the United Kingdom.